FTY720-derived anticancer agents for hepatocellular carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) face challenges due to cellular resistance to conventional cytotoxic agents and the side effects associated with existing therapies like sorafenib, highlighting the need for more effective and less immunosuppressive alternatives.
Innovation Solution
Development of OSU-2S, a non-immunosuppressive analogue of FTY720, which activates reactive oxygen species (ROS)-protein kinase Cδ (PKCδ) signaling independently of sphingosine-1-phosphate (S1P) receptors, thereby suppressing HCC cell growth without affecting normal hepatocytes and causing immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FTY720 is used to induce apoptosis and inhibit angiogenesis in HCC, then antitumor activity is improved, but immunosuppressive effects and cardiovascular complications occur
Solution Approach 1:
The invention segments the pharmacological effects of FTY720 by developing selective analogues (2S, 3S, and 4S) that target specific S1P receptor subtypes. The 2S analogue selectively activates S1P1 and S1P3 receptors while avoiding S1P5, and the 3S/4S analogues selectively activate S1P3. This segmentation allows differentiation between antitumor effects (mediated by specific receptor activation) and immunosuppressive effects (mediated by other receptor interactions), resolving the contradiction by achieving selective therapeutic action.
Solution Approach 2:
The invention applies local quality by creating analogues with differentiated receptor binding properties. Each analogue (2S, 3S, 4S) has distinct pharmacological profiles that selectively engage specific S1P receptor subtypes in tumor cells versus immune cells. This localized selectivity enables the drug to exert antitumor effects through ROS-PKCδ signaling in HCC cells while minimizing immunosuppressive effects by avoiding activation of S1P5 receptors that mediate immune cell recruitment.
2Reliability
If conventional cytotoxic agents are used to treat HCC, then tumor growth is suppressed, but cellular resistance develops due to genetic heterogeneity
Solution Approach 1:
The invention changes the fundamental mechanism of action from conventional cytotoxicity to S1P receptor-mediated apoptosis induction. By developing analogues that activate specific G-protein coupled receptors and trigger ROS-PKCδ signaling pathways, the treatment bypasses the genetic resistance mechanisms that protect HCC cells from traditional chemotherapeutic agents. This parameter change in the mode of action eliminates the basis for cellular resistance while maintaining effective tumor growth suppression.
3Reliability
If sorafenib is used as a multi-kinase inhibitor for HCC, then patient outcome is improved in a subset of patients, but the therapy is not curative and works only in limited cases
Solution Approach 1:
The invention creates a universal therapeutic approach by developing analogues (2S, 3S, 4S) that target the S1P signaling pathway, which is constitutively active in HCC cells regardless of specific genetic mutations. Unlike sorafenib which requires specific kinase pathway dependencies, the S1P analogue approach activates a downstream apoptotic pathway (ROS-PKCδ) that is universally vulnerable in HCC, thereby expanding applicability to all patients while maintaining effective tumor suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
OSU-2S exhibits higher potency in inhibiting HCC cell growth and inducing apoptosis compared to FTY720, with reduced toxicity and immunosuppressive effects, demonstrating significant antitumor activity in both ectopic and orthotopic xenograft models.
Implementation Method 1
activates reactive oxygen species (ROS)-protein kinase Cδ (PKCδ) signaling
Implementation Method 2
activates reactive oxygen species (ROS)-protein kinase Cδ (PKCδ) signaling
Implementation Method 3
inducing apoptosis compared to FTY720
Data Source
AI summary
A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I:wherein R1 is independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; R3 is independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.